UCB (EBR:UCB) UCB Media Room: UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases

Transparency directive : regulatory news

04/03/2024 18:00

https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0r= CyBv9bezcPT-2BuItTLKIHepbxTbo-2FYbVFPSBekB-2Bmk9X7Kl8shoTE6BsSbYYjHYcOVCrOC= rjYrJUHPDVbu1NKaBE-3DISzV_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2= FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLN= n-2B6FohpNoV33yTbcpTnDmS4DjyIHVuahJGTbqwUcYeJ8sm6s-2BqMFx8TaBBFPRqTLJEV548f= 4HggI-2BIW0a0KIG-2FzRUKOVZ-2BxYNLU1-2FNieMLuH1ruOT3VDEWfaTiUXtm-2ByR0qNKJqi= Ib3Rf16kCfnqy0pML5RQvaYyFEGWK4Qz30eshz3dOJ3I2ZKTyAGQAXVFaoBR9feMUaoCJpfZTTy= ObR-2F4GlOVNDH7h5ZzWBS1x3Jpdqi6ItWtEjA-3D ** UCB announces strategic investment in IMIDomics, Inc to advance breakthr= ough solutions for immune-mediated inflammatory diseases ------------------------------------------------------------ Brussels (Belgium), and San Rafeal, CA (US), 4^th March, 2024 (18:00 CET) = =E2=80=93 UCB (Euronext, Brussels: UCB), a global biopharmaceutical company= , today announced a strategic equity investment in IMIDomics, Inc, a privat= e company dedicated to the advancement of novel medicines for immune-mediat= ed inflammatory diseases (IMIDs). =E2=80=9CI am extremely enthusiastic about our investment in IMIDomics. The= ir innovative approach aligns perfectly with our mission to make a meaningf= ul impact on the lives of patients with severe immune-mediated inflammatory= diseases,=E2=80=9D said Dhaval Patel, Executive Vice President and Chief S= cientific Officer at UCB. He continued, "This investment represents more th= an just financial support. It underscores our belief in IMIDomics' potentia= l and our commitment to fostering their pioneering efforts in the field of = immune-mediated inflammatory diseases. We see this as an opportunity to con= tribute to enhancing patient care standards, and to collaboratively support= the progression of medical innovation.=E2=80=9D The parties are also in discussions for a planned research collaboration to= leverage the respective expertise, technologies and assets of both compani= es to accelerate the development of targeted therapies and diagnostic tools= for IMIDs and maximize the indications against which new therapies may be = used. "This strategic investment from UCB is a direct result of our successes in = developing the deepest understanding of IMID patients through our Clinical = Discovery Engine=E2=84=A2, which is based on comprehensive, proprietary pat= ient data and human-centered translation,=E2=80=9D said Fred Craves, CEO of= IMIDomics. =E2=80=9CWe are enthusiastic about the prospect of collaboratin= g with UCB, a company renowned for its commitment to transforming IMID pati= ent outcomes. Together, we look forward to advancing novel solutions that a= ddress the unmet needs of patients suffering from these challenging conditi= ons." Further financial details of the agreement were not disclosed. For further information UCB R&D Communications - Scott Fleming Scott.fleming@ucb.com / T +44 7702777378 Corporate Communications, Media Relations - Laurent Schots laurent.schots@ucb.com / T +3225599264=C2=A0 Investor Relations - Antje Witte antje.witte@ucb.com / T +3225599414 IMIDomics Shani Lewis - slewis@realchemistry.com About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 8,700 peopl= e in approximately 40 countries, the company generated revenue of =E2=82=AC= 5.5 billion in 2022 UCB is listed on Euronext Brussels (symbol: UCB). Follo= w us on Twitter: @UCB_news. About IMIDomics IMIDomics has established itself as a leader in the use of deep, multidimen= sional patient data to generate insights into complex diseases, an approach= that is set to dictate the future of precision IMID therapeutics. Its Clin= ical Discovery EngineTM is built on the foundation of the IMID Investigator= Consortium led by Dr. Sara Marsal, Co-founder and Chief Medical Officer of= IMIDomics, at the Vall d=E2=80=99Hebron Research Institute in Spain, which= has generated comprehensive patient data under a single unified protocol t= hat ensures the quality of the data collected, relevance to disease, and pr= ecise alignment of phenotypic and biomolecular data. These data allow the i= dentification of targets underpinning disease phenotypes and the identifica= tion of those patients who are most likely to respond to new medicines, imp= roving the therapy for patients while streamlining the drug development pro= cess. IMIDomics has identified previously unrecognized targets, six of whic= h have been selected for development within IMIDomics=E2=80=99 active drug = pipeline. To learn more about IMIDomics, please visit www.imidomics.com (ht= tps://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIuSly0rC5= QjCXs4G-2Boh9iOAc-2BXBqNRCZYI0B-2F6r-2FWnaXVttpLk-2FYbK2KTucVGv00729NvNOfnv= GE4ar4ZfADp9az5z14-2B8A4tfP9msygttUC1rYI144h1VBxlARRiPqbcsWK0Amg0Je1OFJcigS= rjpWSLcaKnu49o-2F3QS5-2FTkYpDlRpuIPe-2FdSRfhdHf9VYfreL38f6ibhTYNXITVYHgjxKz= lAhTPAyx2msjH8bD8hMfxP4CLBvqMSgh8qVzPRlGBv0EZoLCYImB01tYTuuDzRaqAmBnmJZ7J86= Cr2mLLsfT6aVvspDbTW4L0JVeff7gN5-2B7UNYEBSvaBSTJs0wT8YFJUfZXfpZVKKlcqdzazk5S= e-2FZXTDXNEss151RACyoq-2BBRQ-2FNHIlM5tMYvTvIQg4uCaO3T-2B2TFjkDJ-2BdBL3wITAE= w0QDOvcm-2Fu-2BAPAtImkYcBeeDIjSpcja956TxhyqaoqjrVrEhnlKRmYKOMwFm1FJfvKGPqgh= Ylg9JVSd36HjNZ7jD0DzM4K4gatggoVj6x-2FBRmO6Es-3Dn_uD_2dCLUNbuBjhX746-2FvM63L= 9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeF= O93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yTbcpTnDmS4DjyIHVuahJGTbqwUcYeJ8sm6= s-2BqMFx8TaBBFPRqTLJEV548f4HggI-2BIW0a0KIG-2FzRUKOVZ-2BxYNO7V39m2kM62Yhg4-2= FT5UpgtnJ6g90X45R5O68iuDG1QMSY9ldWePZM6VvFC9pAQ3VYXs-2BUFJnfmus6Eu5Mm3p4dO1= yJ7cUQ512eRqNHvZXFA1j7lgOO-2F1cYbZ18Ke-2B5WBZEPGwZVMmaTqMIQaZJ2pG0-3D . GenericFile FINAL UCB IMIDomics 28 FEB 76 (https://u7061146.ct.sendgrid.net/ls/click?up= n=3Du001.gqh-2BaxUzlo7XKIuSly0rCyBv9bezcPT-2BuItTLKIHepbMQMPWFc1COLd7gtPXqZ= RPFZA4sm1vOkynsHlAMPqp7GaXnxQwJ87Mt68hLr8UGgs-3DQXQs_2dCLUNbuBjhX746-2FvM63= L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQe= FO93DwfIxs8cV3s33SbkEZvEGLNn-2B6FohpNoV33yTbcpTnDmS4DjyIHVuahJGTbqwUcYeJ8sm= 6s-2BqMFx8TaBBFPRqTLJEV548f4HggI-2BIW0a0KIG-2FzRUKOVZ-2BxYNGnshPROyEmub63Yo= -2BHp5jjY4sUDgY-2BFe-2Fr6ecpMPO3Gwrv9RO-2Bq-2Bmsn0C9sI6m-2BXwd1TwGEjFOXgUCz= Ag5dIuA-2FdDip0iBah1vSEbbbr6mblmTJCfB4CPrFmaqqU4vYM-2FLjsF3R-2FsT7GAh1D5tML= AA-3D ______________________ If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/ls/click?upn=3Du001.gqh-2BaxUzlo7XKIu= Sly0rC3nfmD42E6tJ6HwHGmqtXbhtXDlQ2cTEdRpWV-2BrYPIUNCf1xENBrXWstXvmw8xl-2FST= ItHlxpnLu4NaVTlrKekskGpkW8NWQedhmt9NFij3F1F6qOn9ad-2BcdgGFtwbjopUrkyA2TR3gz= WK9ccMJic-2Bd0-3D48CB_2dCLUNbuBjhX746-2FvM63L9Hyn3KnTFGM-2BPPGCjZgmJl-2FKl1= Z2nt-2BIfez2IJ0TSaz3mplcEW6ZopJ4gUd4Ia3MTdQeFO93DwfIxs8cV3s33SbkEZvEGLNn-2B= 6FohpNoV33yTbcpTnDmS4DjyIHVuahJGTbqwUcYeJ8sm6s-2BqMFx8TaBBFPRqTLJEV548f4Hgg= I-2BIW0a0KIG-2FzRUKOVZ-2BxYNMilq6AlT9ZVCLqBz2DzV6kPywiPbdXO3S8JEhjXFyMpqDc7= hu6i1n-2FjO7p3D0B2cHSwT5yBbwvhZuvcu7-2BuPjHwVJE6D0lcLvJ3cVezq248SpTVq1PnmMV= cIOJXQiQOf73GRoTjNJB1lSwk985tbgY-3D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium

UCB's latest news

25/04/2024 18:00

UCB (EBR:UCB) UCB Media Room: UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases

Transparency directive : regulatory news

UCB's latest news

Other stories